Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARADISE in Kagoshima: Pemafibrate vs Ethyl Icosapentate in Hyperlipidemia with Type 2 Diabetes Mellitus
jRCTs071190049Completed
- Sponsor
- Soiken Holdings
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pemafibrate in hyperlipidemia and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Soiken Holdings. Started Apr 2020; status: completed.
02
Drugs
pemafibrate
03
Conditions
hyperlipidemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs071190049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190049.